The Belgian drugmaker plans to hire about 330 people at a facility that will use advanced manufacturing technologies including AI, robotics and automation to meet rising demand for key products. This will be UCB’s first biologics manufacturing facility in the U.S. UCB is investing $2 billion to build its first biologics manufacturing facility in the U.S., putting down roots in Georgia to support products including the psoriasis drug Bimzelx. Belgium-based UCB unveiled plans to build a biologic

Novartis announced plans to invest more than 3.3 billion yuan (nearly $480 million) to expand its research, production, and operations footprint in China, with a focus on advancing pharmaceutical innovation and radioligand therapy (RLT). According to the announcement , the investment includes the expansion of manufacturing and R&D infrastructure. In Changping, Beijing, the company is upgrading its production site with planned investments of about 1.5 billion yuan (approximately $ 220 million) t

March 24, 2026 -- RyboDyn, Inc., a biotechnology company decoding the dark proteome using an AI-powered novel sequencing and discovery platform, today announced the initial close of a $10M Seed financing from a syndicate of new and existing investors. The financing will accelerate the company's transition from foundational discovery into scaled platform execution and progress early-stage programs into IND-enabling studies. RyboDyn founders Imad Ajjawi, PhD (left), and Corey Dambacher, PhD (righ

March 24, 2026 -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that it has entered into a securities purchase agreement with RA Capital Management for a private placement that is expected to result in gross proceeds of approximately $30 million before deducting placement agent fees and offering expenses, and an additional approximately $44 million of gross proceeds if the accompanying warrants are exerci

Financing co-led by Taiho Ventures and Arkin Bio Capital with significant participation from other new and existing investors Investment enables continued clinical development of T-Bolt™ therapies, including completion of CBX-250 Phase 1 trial and initiation of CBX-663 clinical trial Preclinical and translational updates on both programs to be presented at the American Association for Cancer Research (AACR) 2026 Annual Meeting Crossbow Therapeutics, Inc., a biotechnology company developing a

Funding to advance proprietary T-cell engager platforms and pipeline of highly differentiated T-cell engager therapies targeting solid tumors and autoimmune diseases Financing co-led by multiple top-tier financial investors, with participation from global investors including LAV and Eisai One of the largest seed financing rounds for a Chinese biotechnology company Excalipoint Therapeutics, a biotechnology company developing next-generation T-cell engager (TCE) therapies for cancer and autoimmun

March 17, 2026 – iDEL Therapeutics today announced the closing of a EUR 9 million seed financing, establishing its operations and leadership team. The company is pioneering a pipeline of cancer therapeutics that are delivered directly into the cytosol of tumor cells. iDEL’s new approach is compatible with both large and small molecules and aims to unlock historically undruggable intracellular targets and broaden therapeutic windows across cancer indications. The financing was led by BiomedVC wit

Capital strengthens the advancement of EQ504 through key clinical milestones Anticipated net proceeds, along with existing cash and cash equivalents, expected to extend cash runway into 2029 March 13, 2026 --- Equillium, Inc. (“Equillium” or the “Company”) (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that it has entered into a definitive securities purchase agreement with RA Capital Management that will

Investment led by T&J Meyer Family Foundation, joined by Varia Ventures, NW Angel Fund and other non-institutional investors Financing advances Combat’s HIVEC® HEAT FDA registration trial to change standard of care in BCG unresponsive NMIBC Future financings to progress patented hyperthermic technology aimed at improving chemotherapy therapeutic efficacy, tolerability and treatment outcomes for advanced bladder and peritoneal cancers Combat Medical (Combat), a medical device company optimisin

MindImmune today announced a transformative $5 million award from the Alzheimer’s Drug Discovery Foundation (ADDF) to accelerate development of its lead therapeutic candidate, MITI-101 — a first-in-class program designed to target immune pathways driving neuroinflammation and neurodegeneration in Alzheimer’s disease. This significant funding underscores growing scientific momentum around immune-mediated mechanisms in Alzheimer’s and positions MindImmune at the forefront of a new wave of therape